JPRN-UMIN000003130已完成3 期
Randomized Phase III Trail of Liposomal Doxorubicin(PLD)50mg/m2 versus Liposomal Doxorubicin(PLD)40mg/m2 in Patients with Platinum-Refractory and -Resistant Mullerian Carcinoma (Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma). - Randomized Trial of PLD 50mg/m2 vs PLD 40mg/m2 for Platinum-Refractory and -Resistant Mullerian Carcinoma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients who have a history of hypersensitivity to Doxorubicin 2) Patients with active infection 3) Patients with severe complications (Heart disease, uncontrolled diabetes, malignant hypertension, or bleeding tendency) 4) Patients who have any other cancer within the past 5 years 5) Patients have myocardial infarction within 90 days or angina attack. 6) Patients who have treated prior chemotherapy with Anthracycline of a total dose of more than 250 mg/m2 doxorubicin 7) Patients have received prior PLD chemotherapy. 8) Patients have symptomatic brain metastasis with symptom. 9) Patients are pregnant or breast feeding. 10)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
研究者
相似试验
进行中（未招募）
不适用
A phase II study of Pegylated Liposomal Doxorubicin PLD as preoperative treatment for elderly patients with locally advanced primary breast cancer. - NDocally advanced breast cancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2005-005039-86-ITISTITUTO EUROPEO DI ONCOLOGIA30
招募中
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
已完成
2 期
A Phase II Trial of Liposomal Doxorubicin (PLD) + Carboplatin (CBDCA) as Treatment in Relapsed, Plutinum-sensitive Ovarian CancerOvarian cancerJPRN-UMIN000003944Osaka University Graduate School of Medicine Department of Obstetrics and Gynecology85
进行中（未招募）
不适用
'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients'Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en combinación con Docetaxel (Taxotere) en pacientes con cáncer de mama avanzadoAdvanced Breast CancerEUCTR2005-001499-10-ESDr. José Ramón Mel Lorenzo
进行中（未招募）
不适用
PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER - PACLIDOX 07Operable breast cancer patients (T>2 cm, cT2-3, N0-N2, M0) or potentially operable, locally advanced breast cancer patients (T4, N0-2, M0) or inflammatory breast cancer patients (T4d, N0-2, M0), with or without HER2 overexpression or amplificationMedDRA version: 9.1Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantEUCTR2008-001369-27-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE